 |
 |
   |
 |
 |
|
- QRxPharma Announces Interim Analysis Of Final Pivotal Phase 3 Study For MoxDuo®IR
QRxPharma (ASX: QRX and OTCQX: QRXPY) announced a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140 patients has greater than 90% power to detect differences of analgesic effect, indicating there is no need to enrol additional patients...
- Floridians Prepare To Take Back The State
September's National Pain Awareness Month has never been more important for the state of Florida. Recent data from the Florida Medical Examiner shows residents are dying at a rate of at least 7 per day as a result of prescription drug abuse...
- Surgery To Repair Torn Shoulder Muscles In The Elderly Can Reduce Pain And Improve Function
Repairing torn shoulder muscles in elderly patients is often discouraged because of fears of complications. But a new study conducted at Rush University Medical Center has shown that minimally invasive, or arthroscopic, surgery can significantly improve pain and function...
- BEMA Buprenorphine Phase 2 Study Results Selected For Presentation At Pain Week 2010
BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain...
- After Needle Accidents, Hospitals Face Legal Dilemma If They Test Incapacitated Patients
Anaesthetists are calling for greater clarity on the legal implications of testing incapacitated patients for blood-borne viruses, after a survey found that this is often done following staff needlestick injuries, in possible breach of UK legislation...
- QRxPharma To Sponsor Symposium At 13th World Congress On Pain Meeting
QRxPharma (ASX: QRX and OTCQX: QRXPY) announced it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal. The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain...
- Glenmark Announces The Discovery Of A Novel Chemical Entity 'GRC 17536', A TRPA1 Receptor Antagonist, A Potential First-in-Class Molecule Globally
Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting TRPA1 receptor antagonists for pain and respiratory disorders...
|  |
 |  |
